Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer

被引:26
|
作者
Gandaglia, Giorgio [1 ,2 ]
Sun, Maxine [1 ]
Huc, Jim C. [3 ]
Novara, Giacomo [4 ]
Choueiri, Toni K. [5 ]
Nguyen, Paul L. [6 ]
Schiffmann, Jonas [1 ]
Graefen, Markus [7 ]
Shariat, Shahrokh F. [8 ]
Abdollah, Firas [2 ]
Briganti, Alberto [2 ]
Montorsi, Francesco [2 ]
Quoc-Dien Trinh [9 ]
Karakiewicz, Pierre I. [1 ]
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 3J4, Canada
[2] Univ Vita Salute San Raffaele, Urol Res Inst, Milan, Italy
[3] Calif State Univ Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90032 USA
[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Urol Clin, Padua, Italy
[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol,Div Urol,Med Sch, Boston, MA 02115 USA
[7] Univ Hosp Hamburg Eppendorf, Martini Klin, Hamburg, Germany
[8] Med Univ Vienna, Dept Urol, Vienna, Austria
[9] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Surg,Div Urol,Med Sch, Boston, MA 02115 USA
关键词
Androgen deprivation therapy; Prostate cancer; Side effects; Renal failure; Competing risks; Acute kidney injury; ANDROGEN-DEPRIVATION THERAPY; ACUTE-RENAL-FAILURE; CARDIOVASCULAR-DISEASE; MEN; RISK; MORTALITY; CARCINOMA; GNRH;
D O I
10.1016/j.eururo.2014.01.026
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Androgen deprivation therapy (ADT) might increase the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). Objective: To examine the impact of ADT on AKI in a large contemporary cohort of patients with nonmetastatic PCa representing the US population. Design, setting, and participants: Overall, 69 292 patients diagnosed with nonmetastatic PCa between 1995 and 2009 were abstracted from the Surveillance Epidemiology and End Results-Medicare database. Outcomes measurements and statistical analyses: Patient in both treatment arms (ADT vs no ADT) were matched using propensity-score methodology. Ten-year AKI rates were estimated. Competing-risks regression analyses tested the association between ADT and AKI, after adjusting for the risk of death during follow-up. Results and limitations: Overall, the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p < 0.001). When patients were stratified according to the type of ADT, the 10-yr AKI rates were 31.1% versus 26.0% for men treated with gonadotropin-releasing hormone (GnRH) agonists and bilateral orchiectomy, respectively (p < 0.001). In multivariable analyses, the administration of GnRH agonists (hazard ratio [HR]: 1.24; 95% confidence interval [CI], 1.18-1.31; p < 0.001), but not bilateral orchiectomy (HR: 1.11; 95% CI, 0.96-1.29; p = 0.1), was associated with the risk of experiencing AKI. Our study is limited by its retrospective design. Conclusions: ADT is associated with an increased risk of AKI in patients with nonmetastatic PCa. In particular, the administration of GnRH agonists, but not surgical castration, may substantially increase the risk of experiencing AKI. These observations should help provide physicians with better patient selection to reduce the risk of AKI. Patient summary: The administration of gonadotropin-releasing hormone agonists, but not bilateral orchiectomy, increases the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). These observations should help provide physicians with better patient selection to reduce the risk of AKI in PCa patients. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1125 / 1132
页数:8
相关论文
共 50 条
  • [1] Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
    Van Poppel, Hendrik
    Abrahamsson, Per-Anders
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (10) : 830 - 837
  • [2] Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
    Raja, T.
    Sud, Rahul
    Addla, Sanjai
    Sarkar, Kalyan K.
    Sridhar, P. S.
    Talreja, Vikas
    Jain, Minish
    Patil, Ketaki
    INDIAN JOURNAL OF CANCER, 2022, 59 : S142 - S159
  • [3] Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
    Choi, Seungtaek
    Lee, Andrew K.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 : 107 - 119
  • [4] Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
    George, Daniel J.
    Dearnaley, David P.
    FUTURE ONCOLOGY, 2021, 17 (33) : 4431 - 4446
  • [5] Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
    Crawford, E. David
    Hafron, Jason M.
    Debruyne, Frans
    Wallis, Christopher
    Chang, Steven
    Garnick, Marc B.
    JOURNAL OF UROLOGY, 2024, 211 (01) : 63 - 70
  • [6] Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer
    Teoh, Jeremy Y. C.
    Chan, Samson Y. S.
    Chiu, Peter K. F.
    Poon, Darren M. C.
    Cheung, Ho-Yuen
    Hou, Simon S. M.
    Ng, Chi-Fai
    ASIAN JOURNAL OF ANDROLOGY, 2015, 17 (03) : 493 - 496
  • [7] Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study
    Hong, Chon-Seng
    Chen, Yi-Chen
    Ho, Chung-Han
    Hsieh, Kun-Lin
    Chen, Michael
    Shih, Jhih-Yuan
    Chiang, Chun-Yen
    Chen, Zhih-Cherng
    Chang, Wei-Ting
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [8] Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
    Bonde, Tiago M.
    Garmo, Hans
    Stattin, Par
    Nilsson, Per
    Gunnlaugsson, Adalsteinn
    Swanberg, Daniela
    Robinson, David
    ACTA ONCOLOGICA, 2023, 62 (12) : 1815 - 1821
  • [9] Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study
    Chou, Yi-Sheng
    Wang, Chun-Chieh
    Hsu, Li-Fei
    Chuang, Pei-Hung
    Cheng, Chi-Feng
    Li, Nai-Hsin
    Chen, Chu-Chieh
    Chen, Chien-Liang
    Lai, Yun-Ju
    Yen, Yung-Feng
    CANCER MEDICINE, 2023, 12 (05): : 5536 - 5544
  • [10] Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study
    Ostergren, Peter B.
    Kistorp, Caroline
    Fode, Mikkel
    Bennedbaek, Finn N.
    Faber, Jens
    Sonksen, Jens
    BJU INTERNATIONAL, 2019, 123 (04) : 602 - 611